KalGene, Canadian Research Groups Team on CDx for Metastatic Cancer | GenomeWeb

NEW YORK (GenomeWeb) – KalGene Pharmaceuticals has inked an agreement with three Canadian research entities, the Sunnybrook Research Institute, the Centre for Imaging Technology Commercialization, and the Ontario Cancer Biomarker Network, to develop a companion diagnostic for metastatic cancer.

The Vancouver, British Columbia-based pharmaceutical firm will collaborate with its partners on a prognostic marker test along with a companion therapeutic specifically targeting aggressive cancers, such as metastatic breast, colon, and brain cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.